Kwasy tłuszczowe omega-3 w schizofrenii. Część II: Możliwości zastosowania klinicznego

Autor

  • Joanna Róg Faculty of Human Nutrition and Consumer Sciences, Warsaw University of Life Sciences Autor
  • Ewa Stelmach II Department of Psychiatry and Psychiatric Rehabilitation, Medical University of Lublin Autor
  • Bożena Śpila Psychiatric Outpatient Department of the Independent Public Clinical Hospital No. 1 in Lublin Autor
  • Jacek Gajewski I Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin Autor
  • Dariusz Juchnowicz Department of Psychiatric Nursing, Medical University of Lublin Autor
  • Aleksandra Korzeniowska II Department of Psychiatry and Psychiatric Rehabilitation, Medical University of Lublin Autor
  • Joanna Tomaka I Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin Autor
  • Hanna Karakuła-Juchnowicz I Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin / Department of Clinical Neuropsychiatry, Medical University in Lublin Autor

DOI:

https://doi.org/10.1515/cpp-2016-0025

Słowa kluczowe:

schizofrenia, omega 3, niezbędne nienasycone kwasy tłuszczowe omega 3, kwas dokozaheksaenowy, kwas eikozapentaenowy, randomizowane badanie kliniczne, suplementacja

Abstrakt

Nienasycone kwasy tłuszczowe ω-3 to związki należące do grupy niezbędnych nienasyconych kwasów tłuszczowych (NNKT). Historia odkrycia NNKT sięga lat 30. XX wieku, jednak rosnące zainteresowanie NNKT ω-3 w kontekście zdrowia psychicznego obserwuje się od roku 2000. Ze względu na wielokierunkowość działania związki te stanowią obiecującą formę koterapii wielu chorób, w tym zaburzeń psychicznych. Celem artykułu był przegląd piśmiennictwa dotyczącego klinicznych możliwości zastosowania NNKT ω-3 w terapii schizofrenii. Przedstawiono wyniki badań przedklinicznych w tym zakresie oraz omówione przez autorów mechanizmy działania NNKT- ω-3. Szczegółowo scharakteryzowano randomizowane kontrolowane badania kliniczne (RCTs) oceniające możliwość zastosowania NNKT ω-3 w schizofrenii. Wyniki badań nie są jednoznaczne, co wynikać może z różnorodności metodologicznej prze-prowadzanych interwencji. NNKT ω-3 wydają się być obiecującą formą współleczenia schizofrenii. Konieczne są dalsze badania, które pozwolą na określenie grup chorych, w których interwencja przyniesie oczekiwane rezultaty.

Bibliografia

1. Nakamura M.T., Nara T.Y. Essential fatty acid synthesis and its regulation in mammals. Prostaglandins Leukot Essent Fatty Acids. 2003; 68(2): 145-50.

2. Holman R.T. The slow discovery of the importance of omega 3 essential fatty acids in human health. J Nutr. 1998; 128(2): 427-433.

3. Zeman M., Jirak R., Vecka M., Raboch J., Zak A. N-3 polyunsaturated fatty acids in psychiatric diseases: mechanisms and clinical data. Neuro Endocrinol Lett. 2012; 33(8): 736-48.

4. Lorente-Cebrián S., Costa A.G., Navas-Carretero S., Zabala M., Martínez J.A., Moreno-Aliaga M.J. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem. 2013; 69(3): 633-51..

5. Eriksdotter M., Vedin I., Falahati F., Freund-Levi Y., Hjorth E., Faxen-Irving G., Wahlund L.O., Schultzberg M., Basun H., Cederholm T., Palmblad J.. Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study. J Alzheimers Dis. 2015; 48(3): 805-12.

6. Dunstan J.A., Mori T.A., Barden A., Beilin L.J., Taylor A.L., Holt P.G., Prescott S.L. Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol. 2003; 112(6): 1178-84.

7. Gouveia T.L., Vieira de Sousa P.V., de Almeida S.S., Nejm M.B., Vieira de Brito J.M., Cysneiros R.M., de Brito M.V., Salu B.R., Oliva M.L., Scorza F.A., Naffah-Mazzacoratti Mda G.. High serum levels of proinflammatory markers during epileptogenesis. Can omega-3 fatty acid administration reduce this process? Epilepsy Behav. 2015; 51: 300-5.

8. Farjadian S., Moghtaderi M., Kalani M., Gholami T., Hosseini Teshnizi S. Effects of omega-3 fatty acids on serum levels of T-helper cytokines in children with asthma. Cytokine. 2016; 85:61-6.

9. Marcotte E.R., Pearson D.M., Srivastava L.K. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci. 2001; 26(5): 395-410.

10. Kilts C.D. The changing roles and targets for animal models of schizophrenia. Biol Psychiatry. 2001; 50(11): 845-55.

11. Gama C.S., Canever L., Panizzutti B., Gubert C., Stertz L., Massuda R., Pedrini M., de Lucena D.F., Luca R.D., Fraga D.B., Heylmann A.S., Deroza P.F., Zugno A.I. Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophr Res. 2012; 141(2-3): 162-7.

12. Zugno A.I., Chipindo H.L., Volpato A.M., Budni J., Steckert A.V., de Oliveira M.B., Heylmann A.S., da Rosa Silveira F., Mastella G.A., Maravai S.G., Wessler P.G., Binatti A.R., Panizzutti B., Schuck P.F., Quevedo J., Gama C.S. Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. Neuroscience. 2014; 259: 223-31.

13. Zugno A.I., Chipindo H., Canever L., Budni J., Alves de Castro A., Bittencourt de Oliveira M., Heylmann A.S., Gomes Wessler P., da Rosa Silveira F., Damázio L.S., Mastella G.A., Kist L.W., Bogo M.R., Quevedo J., Gama C.S. Omega-3 fatty acids prevent the ketamine-induced increase in acetylcholinesterase activity in an animal model of schizophrenia. Life Sci. 2015; 121:65-9.

14. Zugno A.I., Canever L., Mastella G., Heylmann A.S., Oliveira M.B., Steckert A.V., Castro A.A., dal Pizzol F., Quevedo J., Gama C.S.. Effects of omega-3 supplementation on interleukin and neurotrophin levels in an animal model of schizophrenia. An Acad Bras Cienc. 2015; 87 (2Suppl): 1475-86.

15. El-Sayed El-Sisi A., Sokkar S.S., El-Sayed El-Sayad M., Sayed Ramadan E., Osman E.Y. Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia. Biomed Pharmacother. 2016; 82: 425-31.

16. Watanabe T., Yamagata N., Takasaki K., Sano K., Hayakawa K., Katsurabayashi S., Egashira N., Mishima K., Iwasaki K., Fujiwara M. Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. 2009; 1249: 222-8

17. Micheau J., Marighetto A. Acetylcholine and memory: a long, complex and chaotic but still living relationship. Behav Brain Res. 2011; 221(2): 424-9.

18. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008; 63(8): 801-8.

19. Fernandes B.S, Steiner J., Berk M., Molendijk M.L., Gonzalez-Pinto A., Turck C.W., Nardin P., Gonçalves C.A. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry. 2015; 20(9): 1108-19.

20. Premack D. Human and animal cognition: continuity and discontinuity. Proc Natl Acad Sci U S A. 2007; 104(35): 13861-7.

21. Amminger G.P., Schäfer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010; 67(2): 146-54.

22. Pawelczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawełczyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res. 2016; 73: 34-44.

23. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001; 158(12): 2071-4.

24. Peet M., Brind J., Ramchand C.N., Shah S., Vankar G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001; 49(3): 243-51.

25. Emsley R., Myburgh C., Oosthuizen P., van Rensburg S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry. 2002; 159(9): 1596-8

26. Bentsen H., Osnes K., Refsum H., Solberg D.K., Bøhmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl Psychiatry. 2013; 3:e335.

27. Jamilian H., Solhi H., Jamilian M. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Glob J Health Sci. 2014; 6(7): 103-8.

28. Emsley R., Chiliza B., Asmal L., du Plessis S., Phahladira L., van Niekerk E., van Rensburg S.J., Harvey B.H. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res. 2014; 158(1-3): 230-5.

29. Peet M., Horrobin D.F.; E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002; 36(1): 7-18.

30. Lally J., Gallagher A., Bainbridge E., Avalos G., Ahmed M., McDonald C. Increases in triglyceride levels are associated with clinical response to clozapine treatment. J Psychopharmacol. 2013; 27(4):401-3.

31. Joy C.B, Mumby-Croft R., Joy L.A. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev. 2006; (3):CD001257.

32. Fusar-Poli P., Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol. 2012; 32(2): 179-85.

33. Amminger G.P., Schäfer M.R., Schlögelhofer M., Klier C.M., McGorry P.D. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015; 6:7934.

Pobrania

Opublikowane

2017-01-31

Numer

Tom 17 Nr 4 (2016): Current Problems of Psychiatry

Dział

Artykuły

Licencja

Prawa autorskie (c) 2017 Autorzy

Creative Commons License

Praca jest udostępniana na licencji Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.